https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51305 Wed 28 Feb 2024 16:11:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30070 Wed 24 Nov 2021 15:53:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55201 90% of patients annually) and five practices with low rates of monitoring HbA1c levels (< 80% of patients annually) from HNELHD, NSW provided the sampling frame. A total of nine GPs were interviewed. The transcripts from the interviews were reviewed and analysed to identify emergent patterns and themes. Results: Overall, GPs were supportive of DAP. They considered that DAP resulted in significant changes in their knowledge, skills, and approach and improved the quality of diabetes care. Taking a more holistic approach to care, including assessing patients with diabetes for co-morbidities and risk factors that may impact on their future health was also noted. DAP was noted to increase the confidence levels of GPs, which enabled active involvement in the provision of diabetes care rather than referring patients for tertiary specialist care. However, some indicated the program could be time consuming and greater flexibility was needed. Conclusions: GPs reported DAP to benefit their knowledge, skills and approach for managing diabetes. Future research will need to investigate how to improve the intensity and flexibility of the program based on the workload of GPs to ensure long-term acceptability of the program.]]> Wed 24 Apr 2024 13:05:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33815 Wed 19 Jan 2022 15:18:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14816 Wed 11 Apr 2018 17:21:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20481 Wed 11 Apr 2018 14:29:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46418 Tue 22 Nov 2022 13:53:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47053 Tue 13 Dec 2022 15:25:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46889 Tue 06 Dec 2022 11:20:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36076 Thu 09 Dec 2021 11:02:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46986 Thu 06 Jul 2023 15:13:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38396 Mon 29 Jan 2024 17:47:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39180 n = 29/32) were included in the current analysis (male: n = 22, 36.07%). DHA-enriched fish oil supplementation increased total testosterone levels in males after adjusting for baseline levels, age and BMI. There was no treatment effect in females. Changes in testosterone levels in males were positively associated with changes to omega-3 PUFAs EPA and DHA and inversely correlated with omega-6 PUFA, arachidonic acid and dihomo-gamma-linolenic acid content in erythrocyte membranes, and was associated with beneficial changes to fasting insulin and HOMA-IR across the course of the study. DHA-enriched fish oil supplementation increases testosterone levels in overweight and obese men. Further research is warranted to substantiate these findings with a larger sample size and a longer follow-up period.]]> Mon 23 May 2022 16:16:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42353 Mon 22 Aug 2022 14:01:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31960 Fri 13 Apr 2018 12:35:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45592 1c) assessment and notification of diabetes services about patients at intervention hospitals with blood glucose levels of 14 mmol/L or more. Main outcome measure: New diagnoses of diabetes and documented follow‐up plans for patients with admission blood glucose levels of 14 mmol/L or more. Results: Blood glucose was measured in 133 837 patients admitted to hospital from an ED. The numbers of new diabetes diagnoses with documented follow‐up plans for patients with blood glucose levels of 14 mmol/L or more were similar in intervention (83/506 patients, 16%) and control hospitals (73/278, 26%; adjusted odds ratio [aOR], 0.83; 95% CI 0.42–1.7; P = 0.61), as were new diabetes diagnoses with or without plans (intervention, 157/506, 31%; control, 86/278, 31%; aOR, 1.51; 95% CI, 0.83–2.80; P = 0.18). 30‐day re‐admission (31% v 22%; aOR, 1.34; 95% CI, 0.86–2.09; P = 0.21) and post‐hospital mortality rates (24% v 22%; aOR, 1.07; 95% CI, 0.74–1.55; P = 0.72) were also similar for patients in intervention and control hospitals. Conclusion: Glucose and Hb_1c screening of patients admitted to hospital from EDs does not alone increase detection of previously unidentified diabetes. Adequate resourcing and effective management pathways for patients with newly detected hyperglycaemia and diabetes are needed. Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12611001007921.]]> Fri 04 Nov 2022 08:55:50 AEDT ]]>